Specialty pharmacies are working with clinicians to transition patients who use Flolan to alternative pulmonary hypertension treatments.

GSK (formerly GlaxoSmithKline), which manufactures Flolan, announced in December that it is experiencing supply issues with Flolan for injection.

The shortage is related to quality concerns in the production process. Specialty pharmacies Accredo and CVS Specialty have limited reserves of Flolan but can’t order new supplies until production resumes. It’s unclear when production will restart.

The Pulmonary Hypertension Association understands that unexpected changes in pulmonary hypertension therapy can be stressful and can lead to many questions. If you have questions about your Flolan prescription, PHA encourages you to contact your health care professionals and specialty pharmacy team.

Flolan is the first drug the Food and Drug Administration approved to treat pulmonary arterial hypertension. The medication comes in 0.5 mg and 1.5 mg doses of freeze-dried powder in single-dose vials and must be mixed with a supplied diluent. There are no supply issues with the pH 12 sterile diluent.

GSK hasn’t identified quality issues for Flolan already in pharmacies.

If you have additional questions, email us or call 240-485-0749.